anesthesia guidelines glp-1 Are Serious Risks of Semaglutide and Other Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia GLP-1 and Anesthesia: Considerations and

Cureus , 16 (8)

T.et al (2012)

She feels the extra weight in the knee she had replaced

placebo preserved 5.5% additional weight loss at 88 weeks Typical taper window / 8 to 16 weeks of stepwise dose reduction before full stop Switching GLP-1s / direct substitution on the same injection day is generally well tolerated per clinical practice guidelines Long-term therapy indication / AACE guidelines classify obesity as a chronic disease requiring ongoing treatment Cardiovascular benefit / SELECT trial showed 20% MACE reduction with semaglutide 2.4 mg over 34.2 months Why stopping a GLP-1 abruptly almost always triggers weight regain Abrupt discontinuation of a GLP-1 receptor agonist removes a pharmacological brake on appetite, gastric emptying, and reward-pathway signaling all at once

Browns-Cream Dr

Through our telehealth-based platform, we provide access to clinical expertise and personalized treatment plans without the need for in-person visits